Goyal, Gaurav
Mayo Clinic
Department of Research Collaborator (limited-tenure), on behalf of the Mayo Clinic Histiocytosis Working Group Mayo Clinic, Rochester, Minnesota, USA.
Citations 1
Efficacy of BRAF-Inhibitor Therapy in BRAF V600E-Mutated Adult Langerhans Cell Histiocytosis
Hazim, Antonious , Ruan, Gordon , Ravindran, Aishwarya , Abeykoon, Jithma P. , Scheckel, Caleb , Vassallo, Robert , Ryu, Jay H. , Hazim, Antonious Z , Ruan, Gordon J , Goyal, Gaurav , Vassallo, Robert , Ravindran, Aishwarya , Ryu, Jay H , Tobin, W. Oliver , Koster, Matthew J. , Bennani, N. Nora , Rech, Karen L. , Young, Jason R. , Shah, Meera , Goyal, Gaurav , Go, Ronald S.
The Oncologist | September 28, 2020 | Volume: 25 | Issue: 12 | Pages: 1001-1004
Abstract Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration–approved treatments in adult LCH to establish optimal first-line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF inhibitors in adult patients with BRAFV600E- LCH proven by biopsy. Our case series is the first to report the use of BRAF inhibitors as first-line therapy in adults with LCH. We also report the efficacy with single-agent dabrafenib in adult LCH. All but one of our patients had favorable response to targeted therapy.